Jefferies reaffirmed its buy rating on GSK, emphasizing four near-term catalysts in the company's oncology pipeline following insights from a New York healthcare conference. GSK plans to present new data on its B7H3 antibody-drug conjugate, a targeted cancer therapy, at a major oncology event later in 2026, alongside updates on its B7H4 program focused on gynecological cancers. Additional phase III trials for B7H3 and progress on treatments like IDRx-42 for gastrointestinal tumors and Blenrep for multiple myeloma are expected soon. GSK also highlights the role of AI and digital pathology in its research, aiming for oncology to significantly boost sales by 2031 and beyond.
Jefferies reaffirmed its buy rating and 2,500p price target on GSK after a New York healthcare conference discussion with GSK's oncology head. The bank emphasized four near-term catalysts in GSK's oncology pipeline, including new data presentations f...
Biotech and pharma mergers and acquisitions (M&A) reached $106 billion across 201 deals in early 2026, driven by urgent needs to replace revenue from expiring drug patents and renewed investor interest. Despite rising interest rates and inflation, de...
UBS describes the UK equity market as an "incomplete plate," favoring selective stock picking over broad index exposure. Earnings are the strongest support, especially in energy and pharmaceuticals, while sentiment remains a drag. The FTSE 100 shows ...
